Description
Applications
The CliniMACS CD1c (BDCA-1)-Biotin Product Line was developed for the enrichment of CD1c (BDCA-1)+ myeloid dendritic cells from human heterogeneous hematologic cell populations in combination with the CliniMACS System.
After labeling of target cells with the CliniMACS CD1c (BDCA-1)-Biotin, the CliniMACS Anti-Biotin Reagent is used for the magnetic enrichment of CD1c (BDCA-1)+ cells from the cellular product. A CD19+ B cell depletion is recommended prior to the enrichment of CD1c (BDCA-1)+ cells, due to expression of CD1c (BDCA-1) on a subset of CD19+ B cells.
Referenced literature
CD1c (BDCA-1) enriched blood MDCs were used in clinical studies for the treatment of melanoma and prostate cancer.5,6
Disclaimer
The CliniMACS® System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485.
In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for in vitro use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans the national legislation and regulations - e.g., for the EU the Directive 2004/23/EC ("human tissues and cells"), or the Directive 2002/98/EC ("human blood and blood components") - must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System.
In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved as a Humanitarian Use Device (HUD), authorized by U.S. Federal law for use in the treatment of patients with acute myeloid leukemia (AML) in first complete remission. The effectiveness of the device for this indication has not been demonstrated. Other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application, Investigational Device Exemption (IDE) or FDA approval.
CR/GMP products are for ex vivo cell processing only, and are not intended for human in vivo applications. CR/GMP products are designed, manufactured and tested under an ISO 13485 quality management system and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials. The manufacturing and testing of CR/GMP products of biological origin are in compliance with EP chapter 5.2.12 for “Raw materials of biological origin for the production of cell-based and gene therapy medicinal products”.
Overview
The CD1c (BDCA-1) antigen belongs to the CD1 family and is involved in presentation of lipid antigens. In human blood, CD1c (BDCA-1) is exclusively expressed on CD11chigh CD123low myeloid dendritic cells and a small subpopulation of CD19+ B cells.1
Myeloid dendritic cells represent the major subset of dendritic cells in human peripheral blood (about 0.3% of white blood cells). They display a strong T cell stimulatory and cross-presenting capacity.2–4
The CliniMACS CD1c (BDCA-1)-Biotin Product Line consists of murine anti-CD1c (BDCA-1) monoclonal antibodies conjugated to biotin.
One vial contains 5 mL sterile, non-pyrogenic solution.
The performance of the CliniMACS CD1c (BDCA-1)-Biotin Product Line depends on the individual separation strategy. For information on respective capacities, refer to the CliniMACS User Manual or contact your local representative.
Please inquire about required CliniMACS System components and accessories.
